Floatz logo

SWI019

Relapsed/Refractory B-cell Lymphomas

Calibr, a division of Scripps ResearchPhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

317 Active assets in the Relapsed/Refractory B-cell Lymphomas cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

SWI019 is also rated in:

marginal zone lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
follicular lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →